Item 8.01. Other Events.
As previously disclosed, the board of directors (the "Board") of LAVA Medtech
Acquisition Corp. (the "Company") has elected to abandon and not implement the
extension that was approved by stockholders on April 25, 2023 and intends to
dissolve and liquidate in accordance with the provisions of its Amended and
Restated Certificate of Incorporation.
The Company will redeem (the "Redemption") all of the outstanding shares of
Class A common stock that were included in the units issued in its initial
public offering (the "Public Shares"), at a per-share redemption price of
approximately $10.44 (the "Redemption Amount") after the payment of taxes and
dissolution expenses. There will be no redemption rights or liquidating
distributions with respect to the Company's warrants, which will expire
worthless. On the date of Redemption, the Public Shares will be deemed cancelled
and will represent only the right to receive the Redemption Amount. The
Redemption is expected to be completed on May 15, 2023.
The Company expects that The Nasdaq Stock Market LLC will file a Form 25 with
the United States Securities and Exchange Commission (the "SEC") to delist the
Company's securities. The Company thereafter expects to file a Form 15 with the
SEC to terminate the registration of its securities under the Securities
Exchange Act of 1934, as amended. The Company anticipates that its securities,
including the Public Shares, will cease trading at or around the close of
business on May 12, 2023.
© Edgar Online, source Glimpses
LAVA MEDTECH ACQUISITION CORP. 